BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced it has closed the acquisition of SciSafe, a privately held multi-facility provider of biological materials storage to the cell and gene therapy and pharmaceutical industries.
SciSafe had 2019 unaudited revenue of $6 million and positive EBITDA and is anticipated to be accretive during 2021. Fourth quarter 2020 revenue is estimated at $1.8 million.
Source: Biospace